FHL2 Antikörper

Produktnummer ABIN1107222

Produktdetails anti-FHL2 Antikörper

Target: FHL2 (Four and A Half LIM Domains 2 (FHL2))

Reaktivität: Human, Maus, Ratte

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser FHL2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Spezifität: The monoclonal antibody F4B2-B11 reacts specifically with the LIM-only protein FHL2. It recognizes the N-terminal Zn-Finger motif, it does not cross react in Western Blot with the FHL1 and FHL3 proteins.

Kreuzreaktivität (Details): Species reactivity (tested):Human, mouse, rat

Aufreinigung: Protein G

Klon: F4B2-B11

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.1 mg/mL

Buffer: PBS, 0.02 % sodium azide, 0.1 % bovine serum albumin

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Store at 2 - 8 °C.

Details zu FHL2

Target: FHL2 (Four and A Half LIM Domains 2 (FHL2))

Andere Bezeichnung: FHL2 / SLIM3 (FHL2 Produkte)

Synonyme: AAG11 antikoerper, DRAL antikoerper, FHL-2 antikoerper, SLIM-3 antikoerper, SLIM3 antikoerper, C76204 antikoerper, FHL2 antikoerper, zgc:92428 antikoerper, zgc:103466 antikoerper, four and a half LIM domains 2 antikoerper, four and a half LIM domains 2a antikoerper, four and a half LIM domains 2b antikoerper, FHL2 antikoerper, Fhl2 antikoerper, fhl2 antikoerper, fhl2a antikoerper, fhl2b antikoerper

Hintergrund: Five proteins share the same structural organization and a high degree of sequence homology in this group: four and a half LIM domain protein (FHL) 1, FHL2, FHL3, FHL4, and activator of cAMP-responsive element (CRE) modulator (CREM) in testis (ACT). LIM domains are constituted by a conserved cysteine- and histidine-rich structure shaped in two repeated zinc fingers first identified in the proteins encoded by the Lin-11, Isl-1, and Mec-3 genes. The LIM domain has been shown to function as a protein-protein interaction domain, and has often been described in association with other functional protein motifs, such as homeobox and kinase domains. FHL2 seems to be a promiscuous coactivator because it modulates the activity of the androgen receptor, CRE-binding protein (CREB), and WT1, although some degree of specificity is present because it is unable to stimulate CREM- and Sp1-dependent transcription. FHL2 expression was originally described to be restricted to the heart but it is inducible in other cell types. FHL2 shows specific interaction with beta-catenin, which requires the intact structure of all four LIM domains of FHL2 and the N-terminus plus the first armadillo repeat region of beta-catenin. FHL2 is a muscle-specific repressor of LEF/TCF target genes and promotes myogenic differentiation by interacting with beta-catenin.Synonyms: DRAL, FHL-2, Four and a half LIM domains protein 2, LIM domain protein DRAL, SLIM 3, Skeletal muscle LIM-protein 3

Gen-ID: 2274

NCBI Accession: NP_001034581

UniProt: Q14192

Pathways: Intracellular Steroid Hormone Receptor Signaling Pathway, Regulation of Lipid Metabolism by PPARalpha